HC Wainwright Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $50.00

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price objective boosted by equities researchers at HC Wainwright from $42.00 to $50.00 in a report released on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 186.20% from the stock’s current price.

A number of other equities analysts also recently weighed in on the stock. William Blair began coverage on shares of Tarsus Pharmaceuticals in a report on Tuesday, July 18th. They issued an “outperform” rating and a $44.00 price target on the stock. Guggenheim boosted their price target on shares of Tarsus Pharmaceuticals from $46.00 to $49.00 and gave the stock a “buy” rating in a report on Monday, September 11th. Finally, Bank of America boosted their price target on shares of Tarsus Pharmaceuticals from $42.00 to $54.00 in a report on Wednesday, July 26th.

Tarsus Pharmaceuticals Price Performance

TARS opened at $17.47 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 12.43 and a quick ratio of 12.43. The company has a market capitalization of $569.87 million, a price-to-earnings ratio of -4.57 and a beta of 0.79. The firm’s fifty day moving average price is $15.63 and its two-hundred day moving average price is $16.89. Tarsus Pharmaceuticals has a 1 year low of $11.33 and a 1 year high of $25.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.09). As a group, analysts anticipate that Tarsus Pharmaceuticals will post -4.81 earnings per share for the current fiscal year.

Insider Activity at Tarsus Pharmaceuticals

In related news, insider Jose M. Trevejo sold 1,604 shares of the business’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $18.00, for a total value of $28,872.00. Following the sale, the insider now directly owns 4,503 shares in the company, valued at approximately $81,054. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Jose M. Trevejo sold 1,604 shares of the company’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $18.00, for a total transaction of $28,872.00. Following the sale, the insider now directly owns 4,503 shares in the company, valued at $81,054. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Bobak R. Azamian sold 8,000 shares of the company’s stock in a transaction dated Wednesday, October 18th. The shares were sold at an average price of $13.24, for a total value of $105,920.00. Following the sale, the chief executive officer now owns 886,106 shares in the company, valued at $11,732,043.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,604 shares of company stock worth $410,312. Company insiders own 11.54% of the company’s stock.

Institutional Trading of Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its stake in Tarsus Pharmaceuticals by 0.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 139,151 shares of the company’s stock worth $1,749,000 after buying an additional 600 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Tarsus Pharmaceuticals by 3.3% during the first quarter. Rhumbline Advisers now owns 28,518 shares of the company’s stock valued at $358,000 after purchasing an additional 924 shares during the period. UBS Group AG boosted its stake in shares of Tarsus Pharmaceuticals by 37.0% during the first quarter. UBS Group AG now owns 4,226 shares of the company’s stock valued at $71,000 after purchasing an additional 1,142 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Tarsus Pharmaceuticals by 13.0% during the fourth quarter. JPMorgan Chase & Co. now owns 11,351 shares of the company’s stock valued at $167,000 after purchasing an additional 1,309 shares during the period. Finally, Royal Bank of Canada boosted its stake in shares of Tarsus Pharmaceuticals by 122.0% during the second quarter. Royal Bank of Canada now owns 2,817 shares of the company’s stock valued at $50,000 after purchasing an additional 1,548 shares during the period. Hedge funds and other institutional investors own 70.02% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.